Ximino is a drug owned by Journey Medical Corp. It is protected by 7 US drug patents filed in 2013. Out of these, 6 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 02, 2027. Details of Ximino's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7541347 | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | Active |
| US7544373 | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | Active |
| US7919483 | Method for the treatment of acne |
Mar, 2027
(2 years from now) | Active |
| US8252776 | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | Active |
| US8268804 | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | Active |
| US7790705 | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | Active |
| US5908838 | Method for the treatment of acne |
Feb, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ximino's patents.
Latest Legal Activities on Ximino's Patents
Given below is the list of recent legal activities going on the following patents of Ximino.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Feb, 2024 | US8268804 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8252776 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2022 | US7919483 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Feb, 2022 | US7790705 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Dec, 2020 | US7541347 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Dec, 2020 | US7544373 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Mar, 2020 | US8268804 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2020 | US8252776 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Sep, 2018 | US7919483 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2018 | US7790705 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Ximino is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ximino's family patents as well as insights into ongoing legal events on those patents.
Ximino's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ximino's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 02, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ximino Generic API suppliers:
Minocycline Hydrochloride is the generic name for the brand Ximino. 26 different companies have already filed for the generic of Ximino, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ximino's generic
Alternative Brands for Ximino
Ximino which is used for treating acne, including inflammatory lesions in moderate to severe cases., has several other brand drugs in the same treatment category and using the same active ingredient (Minocycline Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Abbvie |
| |||||||
| Almirall |
| |||||||
| Bausch |
| |||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Minocycline Hydrochloride. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Minocycline Hydrochloride, Ximino's active ingredient. Check the complete list of approved generic manufacturers for Ximino
About Ximino
Ximino is a drug owned by Journey Medical Corp. It is used for treating acne, including inflammatory lesions in moderate to severe cases. Ximino uses Minocycline Hydrochloride as an active ingredient. Ximino was launched by Journey in 2012.
Approval Date:
Ximino was approved by FDA for market use on 11 July, 2012.
Active Ingredient:
Ximino uses Minocycline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Minocycline Hydrochloride ingredient
Treatment:
Ximino is used for treating acne, including inflammatory lesions in moderate to severe cases.
Dosage:
Ximino is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 90MG BASE | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| EQ 45MG BASE | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| EQ 135MG BASE | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |